FindTrial
Sign In

Investigating the Impact of Diltiazem on Tacrolimus Pharmacokinetics in Chinese Liver Transplant Recipients Based Pop-PBPK Model

Investigating the Impact of Diltiazem on Tacrolimus Pharmacokinetics in Chinese Liver Transplant Recipients Based Pop-PBPK Model

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074163
Enrollment
Unknown
Registered
2023-08-01
Start date
2023-08-01
Completion date
Unknown
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplantation

Interventions

Tacrolimus therapy group:N/A

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Liver transplant recipients 2. Patients who have signed the general sample and information donation informed consent form upon admission 3. Oral administration of Tacrolimus for at least 3 days 4. At least one Tacrolimus concentration

Exclusion criteria

Exclusion criteria: 1. Incomplete patient-related clinical data 2. Living donor liver transplant recipients

Design outcomes

Primary

MeasureTime frame
Concentration of tacrolimus;—

Countries

China

Contacts

Public ContactXiaoping Shi

Zhongshan Hospital, Fudan University

shi.xiaoping@zs-hospital.sh.cn+86 136 5188 7033

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026